Health Trials

Recurrent or Refractory Disease After Standard Therapies

2

Review clinical trials related to Recurrent or Refractory Disease After Standard Therapies. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha/FOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.

Participants needed: 36
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Beijing BiotechUpdated: Jun 1, 2026Locations: 1
Eligibility criteria

Histologically confirmed epithelial ovarian, fallopian tube, or primary peritone... [+7]

Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or a... [+9]

Read more
Status: Recruiting

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha/FOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.

Participants needed: 36
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Beijing BiotechUpdated: Mar 18, 2026Locations: 1
Eligibility criteria

Histologically confirmed epithelial ovarian, fallopian tube, or primary peritone... [+7]

Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or a... [+7]

Read more